NEW YORK, March 3, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether Alnylam and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On February 15, 2024, Alnylam issued a press release announcing its fourth quarter and full year 2023 financial results. Among other items, Alnylam announced fourth-quarter revenue that fell short of analyst expectations. Alnylam further announced a delay in topline data from its HELIOS-B study for amyloidosis therapy vutrisiran, advising that the study results would be available in late June or early July 2024.
On this news, Alnylam’s stock price fell $16.72 per share, or 10.19%, to close at $147.43 per share on February 15, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980
SOURCE Pomerantz LLP
